Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
gammadelta T cells can be an option for adoptive immunotherapy of cancer. The major obstacle to clinical application of gammadelta T cells is their low number and lack of a reliable method to expand them consistently and efficiently. We were able to expand gammadelta T cells with high purity in all donors regardless of their starting repertoire of gammadelta T cells. These ex vivo expanded gammadelta T cells are in early differentiation stage, can efficiently kill various tumors and inhibit growth of human lung cancer xenografts. This new approach for ex vivo expansion of human gammadelta T cells will open new horizons for clinical use of these cells.
Toronto General Research Institute, University Health Network, Toronto, Canada.
Pouneh
P
Dokouhaki
Mei
M
Han
Betty
B
Joe
Ming
M
Li
Michael R
MR
Johnston
Ming-Sound
MS
Tsao
Li
L
Zhang
D000818:Animals; D002454:Cell Differentiation; D049109:Cell Proliferation; D002469:Cell Separation; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007371:Interferon-gamma / Q000378:metabolism; D019169:Jurkat Cells; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D016513:Mice, SCID; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D047368:Tumor Burden; D020298:U937 Cells; D023041:Xenograft Model Antitumor Assays
D016692:Receptors, Antigen, T-Cell, gamma-delta; D007371:Interferon-gamma